United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,771,078.76 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,794 shares of United Therapeutics stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $355.54, for a total value of $2,771,078.76. Following the completion of the transaction, the chief financial officer now owns 5,344 shares of the company’s stock, valued at approximately $1,900,005.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $358.62, for a total value of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Trading Up 1.7 %

UTHR stock traded up $5.94 during midday trading on Tuesday, hitting $355.79. 226,254 shares of the company’s stock were exchanged, compared to its average volume of 478,589. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $15.78 billion, a PE ratio of 16.88, a P/E/G ratio of 1.29 and a beta of 0.57. The business has a 50-day simple moving average of $344.35 and a two-hundred day simple moving average of $301.02.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter last year, the firm posted $5.24 earnings per share. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. On average, sell-side analysts predict that United Therapeutics Co. will post 24.71 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Meiji Yasuda Asset Management Co Ltd. increased its holdings in United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 33 shares during the last quarter. Toronto Dominion Bank boosted its position in shares of United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 37 shares during the period. ClariVest Asset Management LLC boosted its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 42 shares in the last quarter. Finally, Access Investment Management LLC raised its holdings in shares of United Therapeutics by 0.8% in the 2nd quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock valued at $2,314,000 after buying an additional 55 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on UTHR. Jefferies Financial Group increased their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. Bank of America dropped their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Wells Fargo & Company raised their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.